ABOS
Price
$1.12
Change
-$0.09 (-7.44%)
Updated
Jun 27 closing price
Capitalization
69.36M
50 days until earnings call
OVID
Price
$0.30
Change
-$0.04 (-11.76%)
Updated
Jun 27 closing price
Capitalization
22.51M
50 days until earnings call
Interact to see
Advertisement

ABOS vs OVID

Header iconABOS vs OVID Comparison
Open Charts ABOS vs OVIDBanner chart's image
Acumen Pharmaceuticals
Price$1.12
Change-$0.09 (-7.44%)
Volume$5.68M
Capitalization69.36M
Ovid Therapeutics
Price$0.30
Change-$0.04 (-11.76%)
Volume$8.89M
Capitalization22.51M
ABOS vs OVID Comparison Chart in %
Loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABOS vs. OVID commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a Hold and OVID is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (ABOS: $1.12 vs. OVID: $0.30)
Brand notoriety: ABOS and OVID are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 1624% vs. OVID: 903%
Market capitalization -- ABOS: $69.36M vs. OVID: $22.51M
ABOS [@Biotechnology] is valued at $69.36M. OVID’s [@Biotechnology] market capitalization is $22.51M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileOVID’s FA Score has 1 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • OVID’s FA Score: 1 green, 4 red.
According to our system of comparison, OVID is a better buy in the long-term than ABOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 4 TA indicator(s) are bullish while OVID’s TA Score has 3 bullish TA indicator(s).

  • ABOS’s TA Score: 4 bullish, 6 bearish.
  • OVID’s TA Score: 3 bullish, 6 bearish.
According to our system of comparison, ABOS is a better buy in the short-term than OVID.

Price Growth

ABOS (@Biotechnology) experienced а -6.67% price change this week, while OVID (@Biotechnology) price change was -2.71% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ABOS is expected to report earnings on Aug 18, 2025.

OVID is expected to report earnings on Aug 18, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ABOS($69.4M) has a higher market cap than OVID($22.5M). ABOS YTD gains are higher at: -34.884 vs. OVID (-67.656). OVID has higher annual earnings (EBITDA): -56.4M vs. ABOS (-111.98M). ABOS has more cash in the bank: 149M vs. OVID (43M). OVID has less debt than ABOS: OVID (14.4M) vs ABOS (29M). OVID has higher revenues than ABOS: OVID (548K) vs ABOS (0).
ABOSOVIDABOS / OVID
Capitalization69.4M22.5M308%
EBITDA-111.98M-56.4M199%
Gain YTD-34.884-67.65652%
P/E RatioN/AN/A-
Revenue0548K-
Total Cash149M43M347%
Total Debt29M14.4M201%
FUNDAMENTALS RATINGS
OVID: Fundamental Ratings
OVID
OUTLOOK RATING
1..100
13
VALUATION
overvalued / fair valued / undervalued
1..100
27
Undervalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
97
PRICE GROWTH RATING
1..100
65
P/E GROWTH RATING
1..100
94
SEASONALITY SCORE
1..100
n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABOSOVID
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bearish Trend 3 days ago
83%
Bullish Trend 3 days ago
81%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
78%
Bullish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 13 days ago
77%
Bullish Trend 4 days ago
73%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 17 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
71%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ABOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OVID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TRP48.880.92
+1.92%
TC Energy Corp
QTRX6.650.08
+1.22%
Quanterix Corp
NOG28.980.03
+0.10%
Northern Oil and Gas
GNFT3.84N/A
N/A
Genfit SA
RCON2.68-0.01
-0.37%
Recon Technology Ltd.

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with FHTX. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then FHTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
-7.44%
FHTX - ABOS
54%
Loosely correlated
-0.41%
CRBU - ABOS
53%
Loosely correlated
-5.19%
BEAM - ABOS
50%
Loosely correlated
-1.98%
IPSC - ABOS
49%
Loosely correlated
-5.74%
CRSP - ABOS
49%
Loosely correlated
N/A
More

OVID and

Correlation & Price change

A.I.dvisor indicates that over the last year, OVID has been closely correlated with JBIO. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if OVID jumps, then JBIO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OVID
1D Price
Change %
OVID100%
-11.95%
JBIO - OVID
79%
Closely correlated
-0.65%
DNLI - OVID
46%
Loosely correlated
-2.69%
CRNX - OVID
46%
Loosely correlated
-0.10%
SYRE - OVID
45%
Loosely correlated
-4.99%
ABOS - OVID
45%
Loosely correlated
-7.44%
More